Core Insights - Suzhou University has announced procurement intentions for 21 types of scientific instruments, with a total budget of 124 million yuan, expected to be procured by August 2025 [2][3]. Procurement Overview - The procurement includes advanced instruments such as: - Field Emission High-Resolution Transmission Electron Microscopy (FE-HRTEM) with a budget of 16.5 million yuan [8]. - X-ray Photoelectron Spectroscopy (XPS) with a budget of 6 million yuan [10]. - Small Animal In Vivo Optical Imaging System with a budget of 2.5 million yuan [10]. - Gas/Liquid Chromatography Mass Spectrometry with a budget of 3.2 million yuan [10]. - Steady-State Transient Optical System with a budget of 6.7 million yuan [10]. Instrument Details - **Steady-State Transient Optical System**: A crucial tool for studying light-matter interactions, differentiating between steady-state and transient techniques based on time resolution and measurement methods [4]. - **Field Emission High-Resolution Transmission Electron Microscopy (FE-HRTEM)**: An advanced microscopy technique capable of atomic-level resolution for material structure characterization [5]. - **X-ray Photoelectron Spectroscopy (XPS)**: A surface analysis technique that utilizes photoelectric effect principles to analyze the energy distribution of emitted photoelectrons, providing information on elemental types, chemical states, and relative content [6]. Research Strengths and Achievements - Suzhou University has notable research capabilities, with five disciplines ranked in the top 1‰ globally according to ESI, and 17 disciplines in the top 1% [11]. - The university has published significant research in high-impact journals, showcasing breakthroughs in fields like perovskite solar cells and luminescent devices [11]. - The university has established key laboratories focusing on various advanced research areas, contributing to national strategic needs and technological innovation [12][14].

Core Viewpoint - The 2025 BCEIA exhibition showcased significant innovations in chromatography technology, emphasizing efficiency, intelligence, and application-oriented solutions in the industry [4][22]. Company Highlights - **Wanyi Technology**: Launched the LC3500 series liquid chromatography system featuring a new high-pressure infusion system with a maximum pressure of 1500 bar and an intelligent temperature control system with precision of ±0.1℃ [7]. - **Qingdao Shenghan**: Presented the CIC-D180H and CIC-D200E high-pressure ion chromatography instruments, along with the CLC-3200 ultra-high-performance liquid chromatography system, which boasts high accuracy and low cross-contamination [9]. - **Haineng Technology (Wukong Instruments)**: Introduced the CMC-ligand/receptor interaction analyzer for analyzing ligand-receptor interactions, and a complex target analysis instrument combining cell membrane chromatography with liquid chromatography [12][13]. - **Dima Technology**: Showcased a full range of chromatography columns and specialized columns for various applications, including a unique mixed-mode liquid chromatography column [15]. - **Shimadzu**: Celebrated its 150th anniversary by unveiling the GC2050 gas chromatography product and the new i-Series liquid chromatography systems, highlighting innovations tailored for petrochemical analysis [17]. - **Yizhen Analysis**: Displayed customized application solutions based on chromatography technology, including various specialized instruments [19]. - **Nanwei Technology Group**: Exhibited a range of chromatography products across its sub-brands, showcasing a complete solution from chromatography consumables to data processing systems [21]. Industry Trends - The focus of chromatography technology is shifting from hardware breakthroughs to application-driven solutions, with companies developing specialized instruments and methods to meet specific industry needs [22]. - The domestic ultra-high-performance chromatography market is gaining momentum, with products like Wanyi's LC3500 and Qingdao Shenghan's CLC-3200 enhancing competition in the market [22]. - Collaboration across the industry is becoming a new engine for development, with partnerships like Haineng Technology's collaboration with Xi'an Jiaotong University exemplifying the push towards integrated innovation [23]. - The integration of intelligent and automated technologies into chromatography systems is advancing, as seen in Wanyi's SmartLab CDS workstation and Shimadzu's i-Series design, facilitating the digital transformation of laboratories [23].

Core Insights - The biopharmaceutical industry is experiencing an upward trend, with companies showcasing their R&D progress and global market strategies during the recent performance briefing [1] - Companies are optimistic about their development in the second half of the year, driven by high R&D investments and technological advancements [1][4] R&D Progress - Companies like Sailun Biopharma and Haohai Biological are making steady progress in product development and market expansion [1] - Sailun Biopharma plans to introduce new projects, including broad-spectrum anti-snake venom antibodies and recombinant snake venom coagulants by mid-2025 [1][2] - Haohai Biological has several innovative products in the pipeline, including a pain-free cross-linked hyaluronic acid gel for aesthetic medicine, which has entered the registration phase [2] Market Trends - The demand for algal oil DHA products is increasing, driven by the replacement of old national standards for infant formula and rising maternal and infant consumption [2][3] - Jia Bi You's sales of algal oil DHA are growing significantly, with a faster transition from fish oil DHA among major clients [3] Industry Outlook - Companies express confidence in the industry's performance in the second half of the year, with expectations of continued growth in the GLP-1 drug market due to its effectiveness in diabetes and weight loss [4] - Nawei Technology anticipates significant market expansion for GLP-1 and other peptide drugs, projecting a revenue increase of approximately 108% in the first half of 2025 [4] Innovation and Global Expansion - The demand for drug molecular building blocks is recovering, with companies like Bid Pharma expanding their compound libraries to cover mainstream targets [5] - Companies are leveraging AI in synthetic biology to enhance R&D efficiency and reduce costs [5] - Xuan Tai Pharmaceutical is pursuing a diversified market strategy, collaborating with Kalbe Farma in Indonesia to penetrate Southeast Asian markets [6]

Summary of Key Points from Conference Call Records Industry Overview - The global pharmaceutical industry is facing a "patent cliff," with over 40% of revenues affected for many multinational companies, creating opportunities for Chinese innovative drug companies to introduce their assets [1][3][4] - The Chinese innovative drug sector is experiencing a diverse globalization path, including overseas expansion, business development, and joint ventures, with significant collaboration with regions like Europe, Southeast Asia, and the Middle East [1][5] Company Performance - **Hengrui Medicine**: Achieved a revenue growth of 15.88% and a net profit growth of 29.67% in the first half of the year, with expectations for further performance improvement in the second half [1][7] - **Kangfang Biotech**: Reported a revenue increase of 49.20% in the first half of the year, with promising data from its API12 presented at WCLC and ongoing global clinical trials for AK104 [1][8] Market Dynamics - The innovative drug sector showed healthy performance in the first half of the year, with significant contributions from products entering the medical insurance list, enhancing profit margins for companies like Kangfang Biotech, Hengrui Medicine, and others [1][6] - The domestic CRO (Contract Research Organization) industry is entering a new phase after adjustments, with a recovery in overseas demand and a clear trend of Chinese innovative drugs moving into late-stage clinical trials [3][10][11] Future Trends and Drivers - The core driving force for Chinese innovative drugs going global is their breakthrough global competitiveness, particularly in next-generation immunotherapy and antibody-drug conjugates (ADCs) [2][12] - The domestic CRO industry is expected to benefit from sustained global innovation demand, increased R&D spending, and the internationalization of Chinese innovative drugs [12] Geopolitical Impact - Geopolitical factors have influenced the Chinese CRO industry, with concerns arising from U.S. regulations, but these have been alleviated over time as companies enhance their core capabilities and expand overseas [13] Notable Companies and Products - **Innovative Products**: - **Sinda's PD-L1 monoclonal antibody**: Demonstrated promising survival data for patients with solid tumors, indicating a broad international market potential [19] - **Gree Pharmaceutical's GLP-1 drugs**: Showed favorable clinical data with significant market potential due to expected weight loss effects [20][21] - **Leading CDMO Companies**: Companies like WuXi AppTec reported a 21% revenue growth and a 102% increase in net profit, benefiting from the ADC industry and overseas expansion [3][14] Conclusion - The Chinese innovative drug sector is poised for growth, driven by strong performance metrics, a favorable global market environment, and strategic international collaborations. The ongoing developments in clinical trials and product launches are expected to further enhance the competitive landscape for these companies [1][9][22][23][24]

Group 1 - The number of doctoral students in China has surged from 326,700 in 2015 to 676,300 in 2024, more than doubling [1][4] - There is a global trend of increasing doctoral graduates, but structural issues exist in the job market for these graduates [3][4] - A significant portion of doctoral graduates, over two-thirds of 4,500 surveyed in the UK, are employed outside academia, often in roles that do not fully utilize their qualifications [4] Group 2 - There is a mismatch between the supply of graduates and the demand from industries, highlighting the need for better alignment between education and industry requirements [2][5] - Educational institutions are exploring new models for talent cultivation, such as establishing national excellence engineering colleges and reforming engineering graduate programs [6][9] - The CO-OP education model, which combines classroom learning with practical experience, is being implemented in various universities to bridge the gap between academic training and industry needs [9]

9月8日，纳微科技盘中上涨2.05%，截至13:21，报27.32元/股，成交1.22亿元，换手率1.13%，总市值 110.32亿元。 资金流向方面，主力资金净流出59.88万元，特大单买入108.77万元，占比0.89%，卖出569.31万元，占 比4.66%；大单买入2336.54万元，占比19.13%，卖出1935.88万元，占比15.85%。 纳微科技今年以来股价涨55.78%，近5个交易日跌1.73%，近20日跌0.11%，近60日涨26.77%。 今年以来纳微科技已经1次登上龙虎榜，最近一次登上龙虎榜为2月27日，当日龙虎榜净买入-551.56万 元；买入总计1.04亿元 ，占总成交额比20.37%；卖出总计1.09亿元 ，占总成交额比21.45%。 纳微科技所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：中盘、新材料、融资融 券、专精特新等。 截至6月30日，纳微科技股东户数1.51万，较上期增加2.29%；人均流通股26739股，较上期减少2.24%。 2025年1月-6月，纳微科技实现营业收入4.14亿元，同比增长21.74%；归母净利润6330.56万元，同比增 长40.5 ...

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **innovative drug and pharmaceutical industry** in China, highlighting the recovery of PS and PB ratios in Hong Kong's creative sales companies, although they have not yet reached historical highs, indicating a period of recovery [1][2]. Core Insights and Arguments - **Global Competitiveness of Chinese Innovative Drugs**: China possesses advantages in population, domestic demand, manufacturing, supply chain, and rapidly improving innovation capabilities, which are driving Chinese assets to go global. High-quality early-stage products from China are in significant demand in the U.S. market, with leading companies gradually increasing their performance [1][3]. - **Valuation Trends**: The innovative drug sector's valuation is expected to first recover to previous PS levels and then potentially break new highs as more products are launched and clinical data is disclosed. The number of products is projected to increase, which will enhance company valuations [1][4]. - **Performance of Kangfang Biotech**: Kangfang Biotech's data presented at WCLC showed a p-value of 0.000332 and an HR value of 0.78, indicating significant improvement, especially in brain metastasis patients, which is a rare and meaningful finding [1][5]. - **International Conference Participation**: In 2025, over 70 Chinese studies were showcased at ASCO, with ongoing presentations at international conferences like WCLC and ESMO, indicating China's growing international influence in innovative drug development [1][6][8]. Additional Important Content - **Diverse Treatment Areas**: The innovative drug trend is not limited to oncology but also includes immunology, with upcoming data releases at various international conferences, showcasing significant progress in multiple therapeutic areas [1][8]. - **Future Growth Expectations**: The Chinese innovative drug industry is anticipated to continue significant growth in the coming years, with more new data and products expected as operational logic is refined. The collaboration models are diversifying, enhancing China's global pricing power and influence [1][9]. - **Catalysts for Market Impact**: The second half of 2025 is expected to bring several important catalysts for the Chinese innovative drug market, including potential approvals for new products from leading companies like Heng Rui and developments from companies like Innovent Biologics and BeiGene [1][10][11]. - **Heng Rui Pharmaceutical's Performance**: As a leading company, Heng Rui's performance in the first half of 2025 was outstanding, with a significant increase in the number of products contributing to sales, reflecting its strong position in global transactions [1][12]. - **Innovent Biologics' Growth**: Innovent Biologics reported significant revenue growth of 5.95 billion, a 50.6% year-on-year increase, indicating improved operational efficiency [1][13]. - **Kangfang Biotech's Platform Value**: Kangfang Biotech demonstrated strong performance with a 49.2% growth in product revenue, showcasing its platform's value and potential for new dual and multi-antibody assets [1][14]. - **Bai Jie Shen Zhou's Financial Performance**: Bai Jie Shen Zhou reported a 17.5% quarter-on-quarter revenue increase, exceeding expectations, with new data updates expected in the second half of the year [1][16]. Conclusion - The innovative drug industry in China is on a recovery trajectory, with strong growth potential driven by competitive advantages, increasing product launches, and expanding international presence. The upcoming catalysts and ongoing developments in various companies are expected to further enhance the industry's outlook.

Group 1 - The company, Nawei Technology, announced plans to hold a collective performance briefing for the biopharmaceutical and CXO industry on September 15, 2025, from 15:00 to 17:00 [1]

Core Points - The company will hold a collective performance briefing for the bioproducts and CXO industry on September 15, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted online through the Shanghai Stock Exchange Roadshow Center, allowing for interactive text communication [2][3] - Investors can submit questions in advance from September 8 to September 12, 2025, to be addressed during the event [3] Meeting Details - Meeting Date and Time: September 15, 2025, from 15:00 to 17:00 [2] - Meeting Location: Shanghai Stock Exchange Roadshow Center (https://roadshow.sseinfo.com/) [2] - Meeting Format: Online text interaction [2] Participants - Key attendees include Dr. Jiang Biwang (Chairman), Mr. Zhao Shun (Board Secretary and CFO), Professor Wu Anping (Independent Director), and Ms. Ma Jiahui (Securities Affairs Representative) [2] Investor Participation - Investors can participate online during the meeting and will receive timely responses to their questions [2][3] - Contact information for inquiries includes the Securities Affairs Department, phone: 0512-62956018, and email: ir@nanomicro.com [3]

证券代码：688690 证券简称：纳微科技 公告编号：2025-032 苏州纳微科技股份有限公司 关于召开2025年半年度科创板生物制品及CXO行业 集体业绩说明会的公告 会议召开时间：2025 年 9 月 15 日（星期一）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：线上文字互动 投资者可于 2025 年 09 月 08 日（星期一）至 09 月 12 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过投资者关系邮箱 （ir@nanomicro.com）将需要了解和关注的问题提前提供给公司。公司将在文字互 动环节对投资者普遍关注的问题进行回答。 苏州纳微科技股份有限公司（以下简称"公司"）已于 2024 年 8 月 28 日发布 公司 2024 年半年度报告全文及摘要，为便于广大投资者更全面深入地了解公司经 营成果、财务状况，公司计划于 2025 年 09 月 15 日 （星期一） 15:00-17:00 举 行 2025 年半年 ...